Immunology Screening on the iQue Screener
Supported by:
14 September 2015
About this webinar
The iQue® Screener is a flexible assay platform for the analysis of immune cell health and function. This webinar will demonstrate how the iQue Screener automates some of the most common assays for immune-modulators and immunotherapy to enable high throughput screening or large combinatorial experiments. The webinar will also explore more complex assays that utilise the iQue Screener’s multiplexing capabilities to combine multiple assays into a single read that creates unique profiles of immune-related effects.
The following assays will be covered:
- Cell proliferation
- Immunophenotyping
- Cytokine detection
- Cell-mediated killing
This webinar was provided by Intellicyt
IntelliCyt Corporation is the market leader in suspension-cell analysis platforms for immunology and immuno-oncology profiling, antibody discovery, and screening of immune targets in drug discovery and life science research.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
IntelliCyt’s iQue Screener can rapidly and cost effectively profile physiologically-relevant model systems for phenotypic endpoints using multiplexed cell and/or bead-based assays.
Our easy-to-use instruments, software, and reagent kits are optimized to work together and designed to conserve precious samples, use less reagent, and minimize time-to-answer. Our high-content solution offers fast and rich per-cell information that delivers the deep insight that complex biology demands.
The top 10 pharmaceutical companies and premier biotechnology and academic institutes, including leaders in immuno-oncology, have made the iQue Screener platform an integral part of their daily research.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related topics
Screening
Related organisations
IntelliCyt Corporation
